Biogen and Denali's Parkinson's Drug Fails to Meet Trial Goals
In a disappointing turn, Biogen and Denali Therapeutics have reported that their experimental therapy for Parkinson’s disease did not succeed in a key randomized trial intended to slow the progression of the condition.
Editorial Staff
1 min read
Updated 5 days ago
Biogen and Denali Therapeutics have announced that their experimental therapy for Parkinson’s disease has failed to demonstrate efficacy in a recent clinical trial.
The trial aimed to assess the drug's ability to slow the progression of this degenerative brain disorder but did not yield the desired results.
This outcome raises questions about the future of the therapy and its potential impact on the treatment landscape for Parkinson’s disease.